Board of Trustees of The Leland Stanford Junior University Sells 683,568 Shares of Bolt Biotherapeutics, Inc. $BOLT

Board of Trustees of The Leland Stanford Junior University decreased its position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 95.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,978 shares of the company’s stock after selling 683,568 shares during the period. Bolt Biotherapeutics makes up approximately 0.0% of Board of Trustees of The Leland Stanford Junior University’s holdings, making the stock its 19th largest holding. Board of Trustees of The Leland Stanford Junior University owned approximately 1.87% of Bolt Biotherapeutics worth $208,000 at the end of the most recent reporting period.

Analysts Set New Price Targets

BOLT has been the topic of several research reports. HC Wainwright set a $7.00 price objective on Bolt Biotherapeutics and gave the company a “buy” rating in a research report on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, October 8th. Zacks Research upgraded shares of Bolt Biotherapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Finally, Lake Street Capital boosted their price objective on shares of Bolt Biotherapeutics to $75.00 and gave the stock a “buy” rating in a report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bolt Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Bolt Biotherapeutics Price Performance

Shares of BOLT opened at $5.83 on Friday. The firm has a market cap of $11.19 million, a PE ratio of -0.22 and a beta of 0.91. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.56. The firm has a fifty day simple moving average of $5.40 and a two-hundred day simple moving average of $5.99. Bolt Biotherapeutics, Inc. has a 1-year low of $4.59 and a 1-year high of $14.36.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($4.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.40) by $1.94. The business had revenue of $1.80 million for the quarter, compared to the consensus estimate of $0.82 million. On average, equities analysts anticipate that Bolt Biotherapeutics, Inc. will post -1.61 EPS for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.